As of April 30, all listed companies in Yunnan have disclosed their 2023 annual reports. By the end of 2023, there are 41 domestic listed companies in the province, with a total share capital of 69.973 billion shares and a total market value of 773.338 billion yuan. In 2023, the total revenue of 41 listed companies will be 564.474 billion yuan, of which 29 companies will be profitable, and 24 companies will achieve year-on-year revenue growth.
Non-ferrous metal enterprises continue to lead
Wind statistics show that among the 41 listed Yunnan enterprises, 12 have a total operating income of more than 10 billion yuan, of which Yunnan Copper has the highest revenue, reaching 146.985 billion yuan, followed by Yuntianhua, Guiyan Platinum and Yunnan Aluminum, with 69.06 billion yuan, 45.086 billion yuan and 42.669 billion yuan respectively. Among the 29 profitable enterprises, Huaneng Hydropower had the highest net profit attributable to shareholders of the parent company, reaching 7.638 billion yuan, followed by Yuntianhua and Yunnan Baiyao, with 4.522 billion yuan and 4.094 billion yuan respectively. Yunnei Power, I Love My Family, and Yunnan Tourism were the three most loss-making companies, with losses of 1.255 billion yuan, 848 million yuan, and 427 million yuan respectively.
From the perspective of growth capacity, the total operating income of 24 enterprises increased year-on-year, of which ST Jinggu had the highest growth, reaching 420.98%; The net profit attributable to shareholders of the parent company of 21 enterprises increased year-on-year, and Lijiang shares had the highest growth rate of 5971.91%. The net profit attributable to shareholders of the parent company of Shennong Group, I Love My Home, and Zhenan Technology fell the most year-on-year, by 257%, 173.91%, and 141% respectively.
The leading ability of non-ferrous metal and chemical enterprises continues to emerge. In 2023, Yunnan Copper will coordinate and balance production, strengthen quality and efficiency, seize market opportunities, promote extreme operation, and continuously enhance profitability. Yunnan Copper will produce 1.3801 million tons of copper cathode in 2023, hitting a record high, with operating income exceeding 100 billion yuan for three consecutive years and cash flow growing at a compound growth rate of more than 10% for three years. At the same time, Yunnan Copper has made every effort to promote the construction of key development projects, and the construction of the Southwest Copper relocation project has been carried out in an orderly manner; 97,200 tons of new metals were added to copper resources, achieving an annual increase in reserves greater than consumption, and the construction of smart factories and smart mines was steadily promoted.
Guiyan Platinum's total operating income, net profit attributable to shareholders of the parent company, R&D expenses and other indicators all increased year-on-year. The company adheres to the principle of supplementing the chain, extending the chain and strengthening the chain, and further improves the construction capacity of the whole industrial chain. Accelerate the construction of a green and low-carbon recycling base for precious metals, and the first phase of the project of Guiyan Resources (Yimen) Company's modern industrial base for the enrichment and regeneration of precious metal secondary resources was completed as scheduled; Actively integrated into the Guangdong-Hong Kong-Macao Greater Bay Area, Guiyan Resources (Yongxing) Company's rare and precious metal deep processing and analysis and testing service project was launched; Seize the development opportunities of the G60 Science and Technology Innovation Corridor in the Yangtze River Delta, and lay out the rare and precious metals innovation platform and Sheshan Precious Metals New Material Industrial Park in Shanghai.
The industry's leading achievements are outstanding
In 2023, among the 41 listed Yunnan enterprises, Huaneng Hydropower will maintain "two firsts": the market value is 155.34 billion yuan, ranking first, and the net profit attributable to shareholders of the parent company is 7.638 billion yuan, ranking first.
Huaneng Hydropower's main business is the development, construction, operation and management of hydropower and new energy power generation projects, and it is currently a leading large-scale power development and operation enterprise in China, which is responsible for the development of hydropower and new energy resources in the mainstream of the Lancang River. In the face of the current tight system power supply situation and the continuous improvement of new energy penetration, the company actively carried out the joint optimization of cascade hydropower in the Lancang River Basin, and strived to promote the construction of a multi-energy complementary integrated base. The Lancang River Cascade Hydropower Station Group, with Xiaowan and Nuozhadu as the core, has the strongest medium and long-term regulation capacity in the entire southern region, continuously supplies clean energy to the social stability, and is the backbone of the "West-to-East Power Transmission" and "Cloud Power Transmission" of China Southern Power Grid, playing an important role in ensuring the orderly supply of power in the system and accelerating the low-carbon energy transformation.
In 2023, in the face of the severe situation of low hydropower storage on the main grid at the beginning of the year, dry water supply in major river basins, and insufficient hydropower generation capacity, Huaneng Hydropower will give full play to its technical and management advantages in water supply forecasting and cascade joint dispatching, and make use of the storage and replenishment of main reservoirs and flood resource utilization to achieve a significant year-on-year increase in power generation while ensuring the safe and stable supply of power in the system.
In the field of biomedicine, Yunnan Baiyao is firmly in the leading position. Judging from relevant statistics, among biomedical enterprises, Yunnan Baiyao has the highest total operating income, reaching 39.111 billion yuan, achieving a "double growth" in total operating income and net profit attributable to shareholders of the parent company.
In 2023, Yunnan Baiyao will continue to maintain its leading position in the market in multiple business areas, with its core product Yunnan Baiyao (Powder) accounting for 14.5% of the retail market share of systemic Chinese patent medicines for musculoskeletal system bone injuries, ranking first in the market. Yunnan Baiyao aerosol has a retail market share of 91% in the local medicine of musculoskeletal system, joint and muscle pain, ranking first in the market; Yunnan Baiyao Band-Aids accounted for 66.5% of the retail market share of topical hemostatic (drug-containing) Band-Aids, ranking first in the market; Yunnan Baiyao toothpaste accounted for 24.60% of the domestic market share, maintaining the first market share in the industry.
Innovation and R&D drive growth
Statistics show that in 2023, 32 listed companies will have R&D expenses, and the top three R&D expenses are 776 million yuan for Walvax Biotech, 727 million yuan for Enjie, and 550 million yuan for Yuntianhua. Compared with the previous year, the year-on-year growth rate of R&D expenses of Chuanjinnuo and Yunlu exceeded 100%, which were 337.62% and 139.84% respectively.
Walvax Biopharma, a high-tech biopharmaceutical company integrating R&D, production and sales of human vaccines, is in a leading position in the industry in the field of biotechnology drugs represented by new vaccines. The company continues to increase its R&D investment in the field of innovative vaccines, continues to promote the in-depth integration of industry, academia, research and application, and links with well-known domestic universities, research institutes and outstanding enterprises to lay the foundation for the next stage of R&D of a variety of innovative vaccines through all-round resource integration and complementary advantages. Last year, the "Yunnan Vaccine Laboratory (in preparation)" led by Walvax Biotech was officially established, leading the breakthrough development of the biomedical industry in Yunnan Province. The mRNA vaccine for the novel coronavirus variant (Omicron XBB.1.5) developed in cooperation with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. has been approved for emergency use by relevant national departments, marking a breakthrough in the company's independent research and development capabilities of mRNA vaccine technology.
Also attaching importance to research and development is Yuntianhua. In 2023, Yuntianhua will give full play to the advantages of integrated mineralization and large-scale operation, and the main production equipment will maintain efficient operation, and the product output will increase year-on-year. The company also actively carries out the application and transformation of advanced technology at home and abroad, continuously optimizes process technology and equipment, forms a number of integrated optimization technologies, and maintains the advanced level of the industry in the production technology and equipment management of the main device.
Nantian Information has performed well in terms of innovation. The company has increased R&D investment and independent innovation, continued to build core products and core competitiveness, and promoted the transformation and upgrading of information technology. In 2023, the company invested 473 million yuan in R&D, and successively developed and launched an accounting and financial service platform, a data visualization platform, a mobile cockpit, a digital operation and investment management system, etc., to continuously improve customer service capabilities and user experience. Focusing on market demand, we will accelerate the initiation, R&D and production of innovative projects, continue to strengthen innovation leadership, successively establish innovative projects such as the financial ecological collaboration platform and the blockchain platform for the insurance industry, and accelerate the promotion and application of intelligent cloud platforms in the financial industry. (Kunming Daily reporter Zhang Yi)
correlation
Yunnan listed companies become "leading geese" in industrial development
In April 2024, the State Council issued the Several Opinions on Strengthening Supervision and Preventing Risks and Promoting the High-quality Development of the Capital Market. The opinion includes nine parts, which is the third "national nine articles" in the capital market.
In recent years, Yunnan Province has continuously promoted the listing of enterprises and improved the quality of listed companies. The reporter learned from the Yunnan Securities Regulatory Bureau that since the implementation of the action plan for the doubling of enterprise listing in 2019, there have been 9 new domestic listed companies in the province, ranking 19th in the country. The nine new domestic listed companies have raised a total of about 24 billion yuan directly after listing, most of which have been invested in the construction of industrial projects in the province. Since 2019, Yunnan enterprises have achieved equity and debt financing of more than 310 billion yuan through initial listing, refinancing, mergers and acquisitions, and the issuance of corporate bonds.
At present, the quality of listed companies in the province has gradually improved, and it has become the "head goose" leading the industrial development of the province. The number of listed companies in Yunnan is not much, but the overall quality is high, the market capitalization, the industry leading enterprises are many, the average market value ranks 8th in the country, there are Huaneng Hydropower, Yunnan Baiyao and other leading enterprises with a market value of more than 100 billion yuan, industry influence, energy, non-ferrous metals, chemicals, biomedicine, etc. are the advantages of Yunnan listed companies. At the same time, risks in key areas have been steadily prevented and controlled, and the market ecology has been continuously optimized. Yunnan's capital market continued to maintain zero defaults on open market bonds; The classification and rectification of private equity funds is progressing smoothly; Remarkable results have been achieved in the clean-up and rectification of local trading venues.
In order to vigorously promote the listing of enterprises, next, Yunnan Province will strengthen the guidance and cultivation of enterprises in key industrial fields and the mobilization of listing. Vigorously explore high-quality enterprises in the province, do a good job in listing services, and promote more high-quality enterprises with regional industry-driven effects to go public; Promote enterprises to actively go public on the Beijing Stock Exchange, and leverage the multi-level capital market to develop layer by layer; Give full play to the incubation role of the "specialized, special and new" sector of the province's regional equity market, sort out and promote a number of technology-based innovative enterprises, individual champions in the manufacturing industry, specialized and special new "little giant" enterprises and small and medium-sized enterprises in subdivided fields to be listed on the Beijing Stock Exchange, rely on the development and growth of the Beijing Stock Exchange, and leverage the multi-level capital market to develop layer by layer to the Shanghai and Shenzhen Stock Exchanges.
Yunnan Province will also explore and promote the issuance of real estate investment trusts (REITs) in the infrastructure sector to realize the listing of existing assets of enterprises; Do a good job in policy publicity and project combing, and encourage local state-owned enterprises to revitalize assets through the issuance of REITs in accordance with the principle of voluntary and steady promotion of enterprises; Encourage local securities legal entities, accounting firms, law firms, head private equity funds and other capital market institutions to serve enterprises to go public. Reporter Zhang Yi reported
Bethany accelerates the layout of new retail tracks
According to the 2023 annual financial report recently disclosed by Yunnan Bethany Biotechnology Group Co., Ltd., Bethany's strong offline layout of concentrating superior resources is expected to become a new engine for the company's performance growth.
In 2023, Bethany will achieve operating income of 5.52 billion yuan, a year-on-year increase of 10.1%, and the revenue indicators will show strong resilience. In the first quarter of 2024, Bethany achieved operating income of 1.097 billion yuan, a year-on-year increase of 27.1%; The non-net profit was 154 million yuan, a year-on-year increase of 21.94%, and the steady development achieved a breakthrough in performance.
According to the report, Bethany has created a new retail full-touch system with the help of the Internet and artificial intelligence new technologies through the channel strategy of laying the foundation for offline pharmaceutical channels and covering the entire online network, successfully realizing "OMO" cross-border marketing, realizing the mutual penetration of offline and online and the in-depth coverage of consumer groups. Bethany's "Winona" brand has made efforts to offline channels, including professional channels such as OTC chain pharmacies and popular channels such as KA and duty-free shops, steadily exploring the offline direct store model, expanding the scale of various channels and offline layout, enhancing the exposure of the "Winona" brand and products, and reaching end consumers in multiple dimensions and depth. The contribution of offline channels was highlighted, and Bethany's offline sales channels of "reasonable coverage, rapid circulation, and effective sales" continued to be built, with OTC channel revenue of 820 million yuan, a year-on-year increase of 66.1%.
Industry insiders believe that in the long run, "offline reconstruction and return" is the general direction of the industry, and the offline physical retail market will usher in considerable increments; In the short term, offline physical retail is a policy concern under the main theme of industry development, and the value of OTC channel consumption attributes is highlighted. Bethany's strong expansion of offline layout with superior resources is expected to become a new engine for the company's performance growth.
It is understood that Bethany has continued to develop offline channels since entering the OTC pharmacy channel in 2017, and has now entered professional channels such as 90,000 stores of OTC chain pharmacies, as well as offline channels such as offline KA and duty-free stores. According to public reports, in 2023, Bethany will fully launch the "Dermatologist Program" for chain pharmacies to help traditional pharmacies improve their professionalism. The "Winona" brand has in-depth cooperation with 550+ chain brands, landed in more than 60,000 terminal stores, improved the channel category strategy, opened a new model of experience sales, effectively increased the number of stores, and took a key step in the upgrading and transformation of traditional retail pharmacies.
Bethany will accelerate its overseas expansion in 2023, and continue to make breakthroughs in its international industrial capabilities. In 2023, Bethany will lay out overseas markets and establish a Southeast Asia business headquarters in Bangkok, Thailand, in order to build and seize the international new retail, and steadily improve terminal coverage through multiple channels and channels. This year, Bethany will build a localized operation team to truly achieve the brand's overseas expansion and open a new chapter of internationalization. (Kunming Daily reporter Guo Man)